This review studied the effects of dietary supplementation with alpha linolenic acid (ALA) on cardiovascular risk markers. It concluded that although ALA may cause small decreases in fibrinogen and fasting blood glucose, most cardiovascular markers are not affected, and that further trials are needed. The limited reporting makes it difficult to assess the reliability of the review's findings.
The change in the means of each outcome between the start and end of treatment were calculated. The corresponding standard deviations were estimated from the 95% confidence intervals (CIs) or standard errors if they were not reported directly.
Methods of synthesis
How were the studies combined? The studies were combined in a meta-analysis using a fixed-effect model. If statistically significant heterogeneity was detected, a random-effects model was used. Weighted mean differences (WMDs) and 95% CIs were calculated for each outcome. Publication bias was assessed using funnel plots.
How were differences between studies investigated?
Heterogeneity was assessed using a chi-squared test at a 10% significance level. Subgroup analyses by ALA dose and placebo type were conducted.
Results of the review
Fourteen RCTs (n=1,235), of which two (n=57) were crossover trials, were included.
Cholesterol and triglycerides.
There was no significant difference between ALA and placebo for change in total cholesterol (WMD -0.01 mmol/L, 95% CI: -0.08, 0.06), based on 11 studies with significant heterogeneity (P<0.05). There was a statistically significant but clinically unimportant decrease in HDL cholesterol with ALA supplementation (WMD -0.01 mmol/L, 95% CI: -0.02, 0.00), based on 10 studies with no evidence of heterogeneity. There were no significant differences observed for LDL or VLDL cholesterol or for triglycerides.
Body weight and BP.
There was no significant difference between ALA and placebo for change in BMI (WMD -0.04 kg/m2, 95% CI: -0.11, 0.03; 3 studies) or weight (WMD -0.18 kg, 95% CI: -0.72, 0.36; 3 studies). There were also no differences for systolic BP (WMD -0.72 mmHg, 95% CI: -2.01, 0.58; 3 studies) or diastolic BP (WMD -0.17 mmHg, 95% CI: -0.82, 0.48; 3 studies). There was no evidence of heterogeneity for any of these outcomes.
Glucose and fibrinogen.
There was a significant reduction in fasting plasma glucose after ALA supplementation (WMD -0.20 mmol/L, 95% CI: -0.30, -0.10; 2 studies). There was also a significant reduction in fibrinogen (WMD -0.17 micromol/L, 95% CI: -0.30, -0.04; 3 studies). There was no evidence of heterogeneity for either outcome.
Emerging cardiovascular risk markers.
One study reported changes in plasma markers. Vascular cell adhesion molecule 1 was the only marker that was significantly different between treatments.
Other analyses.
Subgroup analyses by placebo type or ALA dose did not show any significant differences (results not presented). Funnel plots suggested no evidence of publication bias (plots not presented).
